Cradle Raises $73M in Series B Funding
Summary
Cradle, an Amsterdam, the Netherlands-based provider of a platform for AI-powered protein engineering, raised $73M in Series B funding. The round was led by IVP with participation from previous investors Index Ventures and Kindred Capital. Led by CEO Stef van Grieken, Cradle provides a machine-learning platform that helps scientists to speed up the development of new therapeutics and bio-based products such as enzymes, antibodies and bio-based materials and chemicals. The platform is also adaptable across multiple assets and use cases for both pharmaceutical and industrial applications including enzymes, antibodies, peptides, vaccines, and therapeutic proteins. Industry leaders such as Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis and Grifols use its generative AI platform for research and development across therapeutics, diagnostics, food, chemical, and agricultural products.